1. Home
  2. TLSA vs ALXO Comparison

TLSA vs ALXO Comparison

Compare TLSA & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

N/A

Current Price

$0.68

Market Cap

145.1M

Sector

Health Care

ML Signal

N/A

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

N/A

Current Price

$1.02

Market Cap

172.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TLSA
ALXO
Founded
2013
2015
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.1M
172.8M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
TLSA
ALXO
Price
$0.68
$1.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
7
Target Price
★ $7.87
$4.60
AVG Volume (30 Days)
522.3K
★ 982.7K
Earning Date
05-01-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 26.36
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$0.86
52 Week High
$1.90
$2.66

Technical Indicators

Market Signals
Indicator
TLSA
ALXO
Relative Strength Index (RSI) 46.12 40.95
Support Level $0.57 $0.86
Resistance Level $1.21 $1.34
Average True Range (ATR) 0.10 0.14
MACD 0.01 -0.01
Stochastic Oscillator 55.24 22.12

Price Performance

Historical Comparison
TLSA
ALXO

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: